Table 1 of Ban, Mol Vis 2011; 17:2533-2543.
Case |
Age |
Gender |
HSCT source |
Underlying disease |
Interval between HSCT and CM analysis (mo) |
Interval between DE onset and CM analysis (mo) |
Interval between HSCT and DE onset (mo) |
DE severity level |
CC |
Clinically affected cGVHD organs |
---|---|---|---|---|---|---|---|---|---|---|
1 | 57 | Male | PBSC | ML | 17 | 1 | 16 | 3 | - | Eye, Skin |
2 | 47 | Male | PBSC | AML | 19 | 6 | 13 | 4 | + | Eye, Skin, Mouth, Liver |
3 | 50 | Male | PBSC | MM | 12 | 1 | 11 | 4 | + | Eye, Mouth |
4 | 47 | Female | BM | MM | 43 | 1 | 42 | 4 | + | Eye, Mouth |
5 | 38 | Female | BM | AML | 12 | 0 | 12 | 2 | - | Eye |
6 | 57 | Male | BM | MDS | 14 | N.A. | N.A. | 3 | + | Eye |
7 | 51 | Male | BM | CML | 120 | 48 | 72 | 2 | - | Eye |
8 | 46 | Female | PBSC | MM | 116 | 108 | 8 | 2 | - | Eye |
9 | 55 | Male | PBSC | AML | 25 | 17 | 8 | 4 | + | Eye, Skin |